Trial Profile
KALETRA in Combination With New Substances (PROTEKT)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Lopinavir/ritonavir (Primary)
- Indications HIV infections
- Focus Adverse reactions
- Acronyms PROTEKT
- Sponsors Abbott Laboratories; AbbVie
- 04 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 08 Jan 2016 Planned End Date changed from 1 Oct 2017 to 1 Jan 2016 as reported by ClinicalTrials.gov.
- 30 Jul 2015 Planned number of patients changed from 550 to 450 as reported by ClinicalTrials.gov.